ENETS Consensus Guidelines
ENETS Consensus Guidelines Update for Colorectal Neuroendocrine NeoplasmsRamage J.K.a · De Herder W.W.b · Delle Fave G.c · Ferolla P.d · Ferone D.e · Ito T.f · Ruszniewski P.g · Sundin A.h · Weber W.i · Zheng-Pei Z.j · Taal B.k · Pascher A.l · all other Vienna Consensus Conference participants
aGastroenterology Department, Hampshire Hospitals NHS Trust, Hampshire, UK; bDepartment of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands; cDepartment of Digestive and Liver Disease, Ospedale Sant'Andrea, Rome, dNET Centre, Umbria Regional Cancer Network, Università degli Studi di Perugia, Perugia, and eDepartment of Endocrine and Metabolic Sciences (DIMI), University of Genoa, Genoa, Italy; fPancreatic Diseases Branch, Kyushu University Hospital, Fukuoka, Japan; gDepartment of Gastroenterology, Beaujon Hospital, Clichy, France; hDepartment of Radiology, Section for Molecular Imaging, University Hospital, Uppsala, Sweden; iDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, N.Y., USA; jDepartment of Endocrinology, Peking Union Medical College Hospital, Beijing, China; kNetherlands Cancer Centre, Lijnden, The Netherlands; lDepartment of Visceral and Transplant Surgery, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
- Taghavi S, Jayarajan SN, Powers BD, Davey A, Willis AI: Examining rectal carcinoids in the era of screening colonoscopy: a surveillance, epidemiology, and end results analysis. Dis Colon Rectum 2013;56:952-959.
- Jung KS, Yun KE, Chang Y, Ryu S, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Park DI: Risk factors associated with rectal neuroendocrine tumors: a cross-sectional study. Cancer Epidemiol Biomarkers Prev 2014;23:1406-1413.
- Yangong H, Shi C, Shahbaz M, Zhengchuan N, Wang J, Liang B, Ruliang F, Gao H, Bo Q, Niu J: Diagnosis and treatment experience of rectal carcinoid (a report of 312 cases). Int J Surg 2014;12:408-411.
- Gleeson F, Levy ML, Dozois EJ, Larson DW, Song L, Boardman LA: Endoscopically identified well-differentiated rectal carcinoid tumors: impact of tumor size on the natural history and outcomes. Gastrointest Endoscopy 2014;80:145-151.
- Park CS, Lee SH, Kim SB, Kim KO, Jang BI: Multiple rectal neuroendocrine tumors: report of five cases. Korean J Gastroenterol 2014;64/2:103-109.
- Al Natour RH, Saund MS, Sanchez VM, Whang EE, Sharma AM, Huang Q, Boosalis VA, Gold JS: Tumor size and depth predict rate of lymph node metastasis in colon carcinoids and can be used to select patients for endoscopic resection. J Gastrointest Surg 2012;16:595-602.
- Weinstock B, Ward SC, Harpaz N, Warner RR, Itzkowitz S, Kim MK: Clinical and prognostic features of rectal neuroendocrine tumors. Neuroendocrinology 2013;98:180-187.
- Smith JD, Reidy DL, Goodman KA, Shia J, Nash GM: A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol 2014;21:2956-2962.
- Lee JL, Yu CS, Kim M, Hong SM, Lim SB, Kim JC: Prognostic impact of diagnosing colorectal neuroendocrine carcinoma using the World Health Organization 2010 classification. Surgery 2014;155:650-658.
- Lee SH, Park SJ, Kim HH, Ok KS, Kim JH, Jee SR, Seol SY, Kim BM: Endoscopic resection for rectal carcinoid tumors: comparison of polypectomy and endoscopic submucosal resection with band ligation. Clin Endosc 2012;45:89-94.
- Jeon JH, Cheung DY, Lee SJ, Kim HJ, Kim HK, Cho HJ, Lee IK, Kim JI, Park SH, Kim JK: Endoscopic resection yields reliable outcomes for small rectal neuroendocrine tumors. Dig Endosc 2014;26:556-563.
- Wu J, Srirajaskanthan R, Ramage J: Rectal neuroendocrine tumor. Dig Endosc 2014;26:532-533.
- McDermott FD, Heeney A, Courtney D, Mohan H, Winter D: Rectal carcinoids: a systematic review. Surg Endosc 2014;28:2020-2026.
- Shigeta K, Okabayashi K, Hasegawa H, Ishii Y, Ochiai H, Tsuruta M, Mukai M, Kameyama K, Uraoka T, Yahagi N, Kitagawa Y: Long-term outcome of patients with locally resected high- and low-risk rectal carcinoid tumors. J Gastrointest Surg 2014;18:768-773.
- Aytac E, Ozdemir Y, Ozuner G: Long term outcomes of neuroendocrine carcinomas (high-grade neuroendocrine tumors) of the colon, rectum, and anal canal. J Visc Surg 2014;151:3-7.
- Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-2012.
- Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T; RADIANT-2 Study Group: Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist 2013;18:46-53.
- Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 2016;103:119-124.
- Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for neuroendocrine neoplasm of the jejunum and ileum. Neuroendocrinology 2016;103:125-138.
- Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Öberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, Krenning E, Reed N, O'Toole D; all other Vienna Consensus Conference participants: ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology 2016;103:144-152.
- Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016;103:153-171.
- Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Öberg K; all other Vienna Consensus Conference participants: ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016;103:172-185.
- Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla JB, Caplin M, O'Toole D, Perren A; all other Vienna Consensus Conference participants: ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 2016;103:186-194.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.